ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib
Company profile
Ticker
OCUL
Exchange
Website
CEO
Antony Mattessich
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
I-THERAPEUTIX INC
SEC CIK
Corporate docs
Subsidiaries
Ocular Therapeutix Europe B.V. • Ocular Therapeutix Securities Corp. ...
OCUL stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
19 Apr 24
8-K
Departure of Directors or Certain Officers
18 Apr 24
8-K
Other Events
29 Mar 24
S-3ASR
Automatic shelf registration
25 Mar 24
S-8
Registration of securities for employees
11 Mar 24
10-K
2023 FY
Annual report
11 Mar 24
8-K
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
11 Mar 24
S-8
Registration of securities for employees
22 Feb 24
8-K
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
22 Feb 24
8-K
Other Events
25 Jan 24
Transcripts
OCUL
Earnings call transcript
2023 Q3
7 Nov 23
OCUL
Earnings call transcript
2023 Q2
7 Aug 23
OCUL
Earnings call transcript
2023 Q1
8 May 23
OCUL
Earnings call transcript
2022 Q4
6 Mar 23
OCUL
Earnings call transcript
2022 Q3
8 Nov 22
OCUL
Earnings call transcript
2022 Q2
9 Aug 22
OCUL
Earnings call transcript
2022 Q1
10 May 22
OCUL
Earnings call transcript
2021 Q4
1 Mar 22
OCUL
Earnings call transcript
2021 Q3
9 Nov 21
OCUL
Earnings call transcript
2021 Q2
10 Aug 21
Latest ownership filings
4
Change in insider ownership
27 Feb 24
SC 13D/A
SUMMER ROAD LLC
27 Feb 24
4
Pravin Dugel
26 Feb 24
4
Sanjay Nayak
26 Feb 24
3
Pravin Dugel
26 Feb 24
3
Sanjay Nayak
26 Feb 24
SC 13G/A
Opaleye Management Inc.
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
Christopher G White
6 Feb 24
4
Philip C. Strassburger
6 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 112.31 mm | 112.31 mm | 112.31 mm | 112.31 mm | 112.31 mm | 112.31 mm |
Cash burn (monthly) | (no burn) | 866.67 k | 6.40 mm | 6.81 mm | 2.58 mm | 5.39 mm |
Cash used (since last report) | n/a | 5.98 mm | 44.18 mm | 46.96 mm | 17.78 mm | 37.21 mm |
Cash remaining | n/a | 106.34 mm | 68.14 mm | 65.36 mm | 94.54 mm | 75.10 mm |
Runway (months of cash) | n/a | 122.7 | 10.6 | 9.6 | 36.7 | 13.9 |
Institutional ownership, Q3 2023
26.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 111 |
Opened positions | 8 |
Closed positions | 30 |
Increased positions | 44 |
Reduced positions | 29 |
13F shares | Current |
---|---|
Total value | 124.85 bn |
Total shares | 40.17 mm |
Total puts | 74.70 k |
Total calls | 161.91 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Opaleye Management | 6.47 mm | $20.31 bn |
Summer Road | 6.12 mm | $19.19 bn |
BLK Blackrock | 5.34 mm | $16.78 bn |
Vanguard | 4.06 mm | $12.75 bn |
Deltec Asset Management | 2.06 mm | $6.47 bn |
STT State Street | 1.78 mm | $5.60 bn |
Geode Capital Management | 1.63 mm | $5.12 bn |
Citadel Advisors | 1.29 mm | $4.05 bn |
Nuveen Asset Management | 1.01 mm | $3.17 bn |
Sectoral Asset Management | 969.35 k | $3.04 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Feb 24 | Summer Road | Common Stock, $0.0001 par value per share | Buy | Acquire P | Yes | No | 7.52 | 930,851 | 7.00 mm | 8,591,401 |
22 Feb 24 | Dugel Pravin | Common Stock | Grant | Acquire A | No | No | 0 | 854,979 | 0.00 | 854,979 |
22 Feb 24 | Dugel Pravin | Stock Option Common Stock | Grant | Acquire A | No | No | 9.7 | 1,282,469 | 12.44 mm | 1,282,469 |
22 Feb 24 | Sanjay Nayak | Common Stock | Grant | Acquire A | No | No | 0 | 80,300 | 0.00 | 180,300 |
22 Feb 24 | Sanjay Nayak | Stock Option Common Stock | Grant | Acquire A | No | No | 9.7 | 244,550 | 2.37 mm | 244,550 |
News
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $16 Price Target
19 Apr 24
Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder
18 Apr 24
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
18 Apr 24
Ocular Therapeutix Reports Topline Phase 1 Data For AXPAXLI In Diabetic Retinopathy; AXPAXLI Was Generally Well Tolerated With No Inflammation Observed
18 Apr 24
The Analyst Verdict: Ocular Therapeutix In The Eyes Of 8 Experts
16 Apr 24
Press releases
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
18 Apr 24
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
16 Apr 24
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
15 Apr 24
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
9 Apr 24
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
6 Apr 24